Lyra's LYR-210 showed significant symptom improvement in CRS patients in the ENLIGHTEN 2 trial, meeting primary and secondary endpoints. Lyra Therapeutics announced positive results from their ...
WATERTOWN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results